Wednesday, 17 July 2019

J&J abandons partnership for Geron’s cancer drug

04 October 2018 | News

Geron expects the transition of the complete imetelstat program to occur over approximately 12 months with operational support from Janssen.

Singapore - Johnson & Johnson has dissolved its four-year-old partnership with Geron for cancer drug imetelstat, wiping two-thirds off the biotechs share price at a stroke.

J&Js Janssen Biotech unit said the decision was down to a strategic portfolio evaluation and prioritisation of assets in its pipeline, but nevertheless is a heavy blow to Geron, raising questions about imetelstats potential in particular and the emerging telomerase inhibitor class in general.

Imetelstat has been conspicuously absent from J&Js R&D presentations for some months, raising eyebrows about the state of the programme, but despite this Gerons share price has tripled since the start of the year on expectation that J&J would extend the $935m partnership, signed in 2014.

Geron expects the transition of the complete imetelstat program to occur over approximately 12 months with operational support from Janssen.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls